ZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-Specific CAR-T Cell Therapy Targeting Relapsed … – P&T Community
|
ZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-Specific CAR–T Cell Therapy Targeting Relapsed …
P&T Community “In vivo preclinical animal studies have demonstrated that these CAR–T cells targeting CD33 exhibit specific killing of AML cells, eliminating disease burden, and significantly enhancing survival compared to controls, and I look forward to evaluating … |
